Melfalan Tillomed

Melphalan, the active ingredient in Melfalan Tillomed, is an alkylating agent presented as an intravenous formulation for oncology use. It is employed to treat certain hematologic and solid tumours, notably multiple myeloma, ovarian cancer, and malignant melanoma, by disrupting DNA replication in rapidly dividing cancer cells.

GNH USA supplies Melfalan Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, providing a reliable source of this chemotherapy agent through a robust and timely distribution network.

Melphalan is used in chemotherapy protocols that target malignant cells in both hematologic and solid tumour categories.

- Multiple myeloma: reduces tumour burden and prolongs survival by eradicating malignant plasma cells. - Ovarian cancer: contributes to tumour shrinkage and improves response rates when combined with other agents. - Malignant melanoma: employed in high‑dose regimens to achieve cytoreduction in advanced disease.

Melphalan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting - Neutropenia (low white‑blood‑cell count) - Anemia - Alopecia (hair loss)

Serious or Rare Side Effects: - Secondary malignancies such as therapy‑related leukemia - Severe infections due to profound immunosuppression - Pulmonary toxicity (interstitial pneumonitis) - Renal impairment or failure

When using melphalan, careful monitoring and specific precautions are recommended to minimize risks.

- Monitor blood counts: perform regular complete blood count tests to detect myelosuppression. - Assess renal function: evaluate serum creatinine and adjust dosing in renal impairment. - Evaluate hepatic function: check liver enzymes before and during therapy. - Avoid use in patients with known hypersensitivity to melphalan or related alkylating agents. - Use effective contraception: both male and female patients should employ reliable birth control during treatment and for a defined period after. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Melphalan can interact with other medicines, influencing its efficacy or toxicity.

Major Interactions (Avoid): - Concomitant use with other myelosuppressive agents (e.g., cyclophosphamide) may cause severe bone‑marrow suppression. - Live vaccines: immunosuppression can reduce vaccine effectiveness and increase infection risk. - High‑dose radiation therapy: combined toxicity may exacerbate tissue damage.

Moderate Interactions (Monitor Closely): - CYP450 inducers (e.g., rifampin) may lower melphalan plasma levels, reducing therapeutic effect. - Anticoagulants (e.g., warfarin) may have altered bleeding risk; monitor coagulation parameters.